ResultsIQ

ResultsIQ › Latest results › Alkem Laboratories Limited

Alkem Laboratories Limited Q1 FY27 results deck summary

NSE: ALKEM · BSE: 539523

Results deck of 14 Aug 2026, summarised by AI from the filing.

Alkem Q1 FY27 revenue ₹37,402 mn up 10.9% YoY, PAT ₹5,200 mn down 21.7%, domestic business outperformed IPM by 100 bps.

Key takeaways

  1. Revenue growth Q1 FY27 total revenue from operations ₹37,402 mn, up 10.9% YoY, with India sales ₹24,978 mn and international sales ₹12,223 mn.
  2. PAT decline PAT after non-controlling interest ₹5,200 mn, down 21.7% YoY, despite EBITDA of ₹7,661 mn at 20.5% margin.
  3. Non-US growth Non-US international sales ₹4,785 mn, up 34.5% YoY, driven by double-digit growth across key markets.
  4. Daman OAI Daman formulations facility received Official Action Indicated (OAI) in August 2026 after April 2026 inspection.

Original filing on BSE

Alkem Laboratories Limited Q1 FY27 results

As filed: Revenue ₹3,740 cr (+11% year on year), EBITDA ₹766 cr (+4% year on year), PAT ₹521 cr (−22% year on year), EBITDA margin 20.5% (−147 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,603 cr (+15% year on year), EBITDA ₹517 cr (+33% year on year), PAT ₹251 cr (+41% year on year), EBITDA margin 14.4% (+195 bps). Score 59 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit before exceptional items growth were above it. EBITDA margin rose 195 bps year on year. Other income 47% of PBT. Tax rate 40%. Revenue fell 4% from last quarter. Share price after the results: −0.5% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹3,737 cr (+11% year on year), EBITDA ₹828 cr (+9% year on year), PAT ₹653 cr (+2% year on year), EBITDA margin 22.2% (−34 bps). Score 47 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 34 bps year on year. Revenue fell 7% from last quarter. Share price after the results: −8.8% in 28 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹4,001 cr (+17% year on year), EBITDA ₹921 cr (+22% year on year), PAT ₹779 cr (+11% year on year), EBITDA margin 23.0% (+97 bps). Score 62 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 97 bps year on year. Tax rate 13%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Share price after the results: −2.4% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹3,371 cr (+11% year on year), EBITDA ₹740 cr (+22% year on year), PAT ₹668 cr (+21% year on year), EBITDA margin 22.0% (+190 bps). Score 57 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 190 bps year on year. Tax rate 13%. Share price after the results: +11.3% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹3,144 cr (+7% year on year), EBITDA ₹390 cr (−3% year on year), PAT ₹322 cr (+6% year on year), EBITDA margin 12.4% (−129 bps). Score 35 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 129 bps year on year. Other income 37% of PBT. Revenue fell 7% from last quarter. Share price after the results: −6.8% in 29 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹3,374 cr (+2% year on year), EBITDA ₹759 cr (+7% year on year), PAT ₹641 cr (+6% year on year), EBITDA margin 22.5% (+123 bps). Score 33 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 123 bps year on year. Tax rate 12%. Profit fell 9% from last quarter.
  • Q2 FY25: Revenue ₹3,415 cr (−1% year on year), EBITDA ₹753 cr (+1% year on year), PAT ₹702 cr (+14% year on year), EBITDA margin 22.1% (+33 bps). Score 34 of 100, Below trend. EBITDA margin rose 33 bps year on year. Tax rate 10%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Alkem Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.